VIII factors for the treatment of type A hemophilia
US8623824B2 · kind B2 · utility
0Cited by
17References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 22, 2008 |
| Grant date | Jan 7, 2014 |
| Priority date | — |
| Expiry date | Mar 16, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to improved human FVIII variants having at least one substitution in the A2 and/or C2 domain. The present invention also relates to their uses in the treatment of hemophilia A, particularly in patients with inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.